A Pilot Pharmacodynamic Study to Assess the Anti-proliferative Activity a of the Poly ADP Ribose Polymerase (PARP) Inhibitor Olaparib in Patients With Human Papilloma Virus (HPV) Positive and Human Papilloma Virus (HPV) Negative Head and Neck Squamous Cell Carcinoma (HNSCC)

Trial Profile

A Pilot Pharmacodynamic Study to Assess the Anti-proliferative Activity a of the Poly ADP Ribose Polymerase (PARP) Inhibitor Olaparib in Patients With Human Papilloma Virus (HPV) Positive and Human Papilloma Virus (HPV) Negative Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Olaparib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Jan 2018 Planned End Date changed from 1 Jul 2017 to 1 Jul 2019.
    • 11 Jan 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Jan 2019.
    • 11 Jan 2018 Planned initiation date changed from 1 Dec 2016 to 1 Jan 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top